FDA grants Baxter's Guibao Orencia breakthrough treatment
-
Last Update: 2020-06-07
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
today, the U.SFDA(http://granted its Orencia breakthrough therapy to prevent moderate to severe acute transplantation (GvHD) from non-related donor hema
topoietic stem cell transplants, the company announcedhttp://Orencia treats autoimmune diseases by interfering with the immune activity of T cellsOrencia is a fusion protein consisting of the FC region of CTLA-4 extracellular domain and the fc region of immunoglobulin IgG1In order for T cells to be activated and produce an immune response, antigen-presenting cells (APVC) must submit two signals to T cellsOne is the main tissue-compatible complex (MHC) that is combined with antigens, and the other signal is the CD80/86 moleculeOrencia specifically binds to CD80/86 molecules effectively, intercepting the second signal, so That T cells cannot be immunizedPreviously, Orencia has been approved by the FDA to treat adult patients with active psoriasis arthritis (PsA) and rheumatoid arthritis (RA), as well as adolescent patients with iadearthritis (JIA)The determination of this breakthrough therapy is based on the positive results obtained by Orencia in a Phase 2 clinicaltrial(http://to assess the effectiveness of the prevention of severe acute GvHD after the addition of Orencia in the GvHD Standard Prevention ProgramThis method can be used to treat patients with blood malignant tumors that receive a blood tumor from a non-related donor stem cell transplant, regardless of whether HLA matches or not
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
